New platform targets specific cancer mutations to destroy proteins
A lipoprotein-biomimetic nanoplatform uses macropinocytosis to degrade proteins in KRAS-mutated cells.
Researchers developed KRASTAC, a lipoprotein-biomimetic nanoplatform. This platform targets KRAS-mutated (MT) tumor cells for protein degradation.
KRASTAC hijacks enhanced macropinocytosis in KRAS-MT cells. Macropinocytosis is a route for lysosome-targeting protein degradation.
The platform degrades proteins like epidermal growth factor receptor and programmed cell death ligand 1 (PD-L1). It works at a low antibody concentration of nM within h.
KRASTAC has minimal impact in KRAS wild-type (WT) cells. It shows mutation-specific tumor accumulation and protein degradation in vivo.
In mice with Kras-MT tumors, KRASTAC-induced PD-L1 degradation leads to robust antitumor efficacy. This also reprograms the immunosuppressive microenvironment.
Key facts
- KRASTAC degrades proteins in KRAS-MT cells at nM within h.
- The platform uses macropinocytosis to target the lysosome for protein degradation.
- KRASTAC-induced PD-L1 degradation shows antitumor efficacy in mice with Kras-MT tumors.